Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Webber

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Vaccine|September 6, 2021
Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 yearsJody Lawrence, Nicholas Kitchin, Annaliesa S Anderson, et al.
Vaccine|February 13, 2018
Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adultsJosé A Suaya, Qin Jiang, Daniel A Scott, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2019
A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsNicholas Kitchin, Shon A Remich, James Peterson, et al.
The Journal of Infectious Diseases|August 2, 2023
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsShon Remich, Nicholas Kitchin, James Peterson, et al.
Vaccine|June 4, 2019
A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the NetherlandsBradford D Gessner, Qin Jiang, Cornelis H Van Werkhoven, et al.
BMC Infectious Diseases|June 20, 2020
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 yearsCharissa Fay Corazon Borja-Tabora, Paula Peyrani, Chris Webber, et al.
Obesity (Silver Spring, Md.)|February 15, 2007
Adipocyte enhancer-binding protein 1 modulates adiposity and energy homeostasisHyo-Sung Ro, Lei Zhang, Amin Majdalawieh, et al.
Vaccine|November 17, 2023
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of ageShane Christensen, Salim Bouguermouh, Kumar Ilangovan, et al.
Vaccine|June 5, 2018
A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the NetherlandsBradford D Gessner, Qin Jiang, Cornelis H Van Werkhoven, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 12, 2018
The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage in the Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) StudyAnna M M van Deursen, Marlies A van Houten, Chris Webber, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Vaccine|September 6, 2021
Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 yearsJody Lawrence, Nicholas Kitchin, Annaliesa S Anderson, et al.
Vaccine|February 13, 2018
Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adultsJosé A Suaya, Qin Jiang, Daniel A Scott, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2019
A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsNicholas Kitchin, Shon A Remich, James Peterson, et al.
The Journal of Infectious Diseases|August 2, 2023
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsShon Remich, Nicholas Kitchin, James Peterson, et al.
Vaccine|June 4, 2019
A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the NetherlandsBradford D Gessner, Qin Jiang, Cornelis H Van Werkhoven, et al.
BMC Infectious Diseases|June 20, 2020
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 yearsCharissa Fay Corazon Borja-Tabora, Paula Peyrani, Chris Webber, et al.
Obesity (Silver Spring, Md.)|February 15, 2007
Adipocyte enhancer-binding protein 1 modulates adiposity and energy homeostasisHyo-Sung Ro, Lei Zhang, Amin Majdalawieh, et al.
Vaccine|November 17, 2023
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of ageShane Christensen, Salim Bouguermouh, Kumar Ilangovan, et al.
Vaccine|June 5, 2018
A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the NetherlandsBradford D Gessner, Qin Jiang, Cornelis H Van Werkhoven, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 12, 2018
The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage in the Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) StudyAnna M M van Deursen, Marlies A van Houten, Chris Webber, et al.
Pageof 4